Why the study?
Do small molecule inhibitors reduce viral shedding in a mouse model of persistent norovirus infection?
Do small molecule inhibitors reduce viral shedding in a mouse model of persistent norovirus infection?
This paper provides a detailed protocol for evaluating the efficacy of small molecule antivirals against persistent norovirus infection in a mouse model.
Answers are grounded in this paper and cite their sources.
Provides standardized protocol for antiviral testing in norovirus mouse model; leaves open translation to human efficacy.
Human norovirus is the most common cause of acute gastroenteritis worldwide, resulting in estimated mortality of ~210,000 each year, of whom most are children under the age of five. However, norovirus can infect people of all age groups. There is a risk of prolonged infection in children, the elderly and patients who are immunocompromised. To study the inhibition of persistent norovirus replication by small molecule antivirals in vivo, we used a murine norovirus CR6 strain (MNV.CR6). We demonstrated earlier that efficient small molecules can reduce viral shedding in the stool of infected mice. Here we present how to generate the MNV.CR6 virus stock, infect type I and II interferon receptor knockout AG129 mice via oral gavage, administer antivirals to mice, and quantify viral genome copies in the stool of these mice.
No takes yet. Share an insight, caveat, or question.
Dycke et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: